Finally, recipients of Selplg–/– AML from untreated (saline-injected) donors showed a delayed leukemia onset compared to matching saline-injected WT AML, with a median survival of 22.5 days compared to 15 days, respectively (Figure 5C), despite a similar donor tumor burden in both groups. The gene discussed is SELPLG; the disease is acute myeloid leukemia.